Overexpression of activated protein c is detrimental during severe experimental gram-negative sepsis (Melioidosis)

Critical Care Medicine

Volumn 41, Issue 10, 2013, Pages

  Kager, Liesbeth M ^a,b   Wiersinga, W Joost ^a,b   Roelofs, Joris J T H ^b   De Boer, Onno J ^b   Meijers, Joost C M ^b   Isermann, Berend ^c   Van'T Veer, Cornelis ^a,b   Van Der Poll, Tom ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Activated protein C; Coagulation; Inflammvation; melioidosis; Pneumonia; sepsis

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; BLOOD; BURKHOLDERIA PSEUDOMALLEI; CONTROLLED STUDY; DRUG BLOOD LEVEL; GENE OVEREXPRESSION; GRAM NEGATIVE SEPSIS; HISTOPATHOLOGY; IMMUNE RESPONSE; LIVER; LUNG; MELIOIDOSIS; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SPLEEN; WILD TYPE;

ANIMALS; BLOOD COAGULATION DISORDERS; BURKHOLDERIA PSEUDOMALLEI; CYTOKINES; LUNG; MELIOIDOSIS; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; PROTEIN C; SEVERITY OF ILLNESS INDEX;

EID: 84884839551     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31828a4316     Document Type: Article

References (42)

1. Delvaeye M, Conway EM: Coagulation and innate immune responses: can we view them separately? Blood 2009; 114:2367-2374
2. Levi M, van der Poll T: Inflammation and coagulation. Crit Care Med 2010; 38:S26-S34
3. Esmon CT: Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 32:49-60
4. Mosnier LO, Zlokovic BV, Griffin JH: The cytoprotective protein C pathway. Blood 2007; 109:3161-3172 (Pubitemid 46572500)
5. Shaw AD, Vail GM, Haney DJ, et al: Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis. J Crit Care 2011; 26:539-545
6. Choi G, Schultz MJ, Levi M, et al: Protein C in pneumonia. Thorax 2005; 60:705-706
7. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709 (Pubitemid 32204987)
8. Ranieri VM, Thompson BT, Barie PS, et al: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-2064
9. Mitka M: Drug for severe sepsis is withdrawn from market, fails to reduce mortality. JAMA 2011; 306:2439-2440
10. Angus DC: Drotrecogin alfa (activated).a sad final fizzle to a rollercoaster party. Crit Care 2012; 16:107
11. Currie BJ, Ward L, Cheng AC: The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 2010; 4:e900
12. Wiersinga WJ, van der Poll T, White NJ, et al: Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 2006; 4:272-282
13. Wiersinga WJ, Meijers JC, Levi M, et al: Activation of coagulation with concurrent impairment of anticoagulant mechanisms correlates with a poor outcome in severe melioidosis. J Thromb Haemost 2008; 6:32-39
14. Koh GC, Meijers JC, Maude RR, et al: Diabetes does not influence activation of coagulation, fibrinolysis or anticoagulant pathways in Gramnegative sepsis (melioidosis). Thromb Haemost 2011; 106:1139-1148
15. LaRosa SP, Opal SM, Utterback B, et al: Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei. Int J Infect Dis 2006; 10:25-31 (Pubitemid 43003588)
16. Isermann B, Vinnikov IA, Madhusudhan T, et al: Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007; 13:1349-1358 (Pubitemid 350073598)
17. Wiersinga WJ, Wieland CW, Dessing MC, et al: Toll-like receptor 2 impairs host defense in gram-negative sepsis caused by Burkholderia pseudomallei (Melioidosis). PLoS Med 2007; 4:e248
18. Kager LM, Wiersinga WJ, Roelofs JJ, et al: Plasminogen activator inhibitor type I contributes to protective immunity during experimental Gramnegative sepsis (melioidosis). J Thromb Haemost 2011; 9:2020-2028
19. Kager LM, Wiersinga WJ, Roelofs JJ, et al: Endogenous tissue-type plasminogen activator impairs host defense during severe experimental Gramnegative sepsis (melioidosis)*. Crit Care Med 2012; 40:2168-2175
20. Rijneveld AW, Levi M, Florquin S, et al: Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002; 168:3507-3511 (Pubitemid 34250418)
21. Macias WL, Dhainaut JF, Yan SC, et al: Pharmacokineticpharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 2002; 72:391-402 (Pubitemid 35178865)
22. Easton A, Haque A, Chu K, et al: A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J Infect Dis 2007; 195:99-107 (Pubitemid 44958231)
23. Macias WL, Nelson DR: Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 2004; 32:S223-S228
24. Fisher CJ Jr, Yan SB: Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000; 28:S49-S56
25. Toussaint S, Gerlach H: Activated protein C for sepsis. N Engl J Med 2009; 361:2646-2652
26. Nick JA, Coldren CD, Geraci MW, et al: Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004; 104:3878-3885 (Pubitemid 39620133)
27. van der Poll T, Levi M, Nick JA, et al: Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005; 171:1125-1128 (Pubitemid 40663724)
28. Schouten M, van't Veer C, van den Boogaard FE, et al: Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia. J Infect Dis 2010; 202:1600-1607
29. Schouten M, van't Veer C, Roelofs JJ, et al: Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia. Thromb Haemost 2011; 106:1189-1196
30. Tan CK, Chan KS, Yu WL, et al: Successful treatment of life-threatening melioidosis with activated protein C and meropenem. J Microbiol Immunol Infect 2007; 40:83-87
31. Kerschen EJ, Fernandez JA, Cooley BC, et al: Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204:2439-2448 (Pubitemid 47529328)
32. Slofstra SH, Groot AP, Maris NA, et al: Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br J Pharmacol 2006; 149:740-746 (Pubitemid 44748066)
33. Maniatis NA, Letsiou E, Orfanos SE, et al: Inhaled activated protein C protects mice from ventilator-induced lung injury. Crit Care 2010; 14:R70
34. Murakami K, Okajima K, Uchiba M, et al: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996; 87:642-647 (Pubitemid 26030319)
35. Murakami K, Okajima K, Uchiba M, et al: Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997; 272:L197-L202
36. Choi G, Hofstra JJ, Roelofs JJ, et al: Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med 2007; 35:1362-1368 (Pubitemid 46642667)
37. Robriquet L, Collet F, Tournoys A, et al: Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respir Res 2006; 7:41
38. Schuepbach RA, Velez K, Riewald M: Activated protein C up-regulates procoagulant tissue factor activity on endothelial cells by shedding the TFPI Kunitz 1 domain. Blood 2011; 117:6338-6346
39. Ruf W: New players in the sepsis-protective activated protein C pathway. J Clin Invest 2010; 120:3084-3087
40. Kerschen E, Hernandez I, Zogg M, et al: Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest 2010; 120:3167-3178
41. Cao C, Gao Y, Li Y, et al: The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest 2010; 120:1971-1980
42. Elphick GF, Sarangi PP, Hyun YM, et al: Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood 2009; 113:4078-4085